Actively Recruiting
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Led by Henry Ford Health System · Updated on 2026-05-01
110
Participants Needed
1
Research Sites
268 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
CONDITIONS
Official Title
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 to 80 years old with a diagnosis of a hematological malignancy
- Meet the bone marrow transplant program criteria to undergo hematopoietic stem cell transplantation for blood cancers
You will not qualify if you...
- Patients currently enrolled in other investigational clinical trials
- Patients undergoing stem cell transplant for non-hematologic malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henry Ford Health System
Detroit, Michigan, United States, 48202
Actively Recruiting
Research Team
S
shatha farhan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here